A Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
An open label phase I/IIa study to evaluate the safety and tolerability of 6 different doses/
infusion rates of subcutaneous (SC) ND0612 solution in PD patients; to determine if
continuous delivery of levodopa and carbidopa can provide reduced variability in plasma
concentration; to test and compare the PK profile of high and low concentrations of CD; to
assess preliminary efficacy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
NeuroDerm Ltd.
Collaborator:
Michael J. Fox Foundation for Parkinson's Research